P3.11-25 Analysis Indicates Low Incremental Cost-Effectiveness Ratio for Implementation of Lung Cancer Screening in Italy

Giulia Veronesi; Simone Ghislandi; Elena Vanni; Elisa Dieci; Luca Toschi; Laura Velutti; Michela Solinas; Pierluigi Novellis; Marco Alloisio; Elio Riboli; Niccolò Navone

doi:10.1016/j.jtho.2018.08.1821

Related publications

Article2025

Effectiveness and cost-effectiveness of risk-adapted colorectal cancer screening: a randomized controlled trial and modeling analysis

Hongda Chen, Bin Lu, Jufang Shi, Yueyang Zhou, Lingbin Du, Xianzhen Liao, Donghua Wei, Dong Dong, Yi Gao, Chen Zhu, Rongbiao Ying, Weifang Zheng, Shipeng Yan, Haifan Xiao, Juan Zhang, Yunxin Kong, Furong Li, Na Li, Jia‐Hui Luo, Chenyu Luo, Hermann Brenner, Min Dai

Article2017

Cost-Effectiveness Analysis of Empagliflozin In The Treatment Of T2d With Previous Cardiovascular Disease In Italy

Sergio Iannazzo, Edoardo Mannucci, Odette S. Reifsnider, Aldo Maggioni

Article2017

Pleural plaques in lung cancer screening by low-dose computed tomography: prevalence, association with lung cancer and mortality

Mario Silva, Nicola Sverzellati, Davide Colombi, Gianluca Milanese, Carlo La Vecchia, Carlotta Galeone, Alfonso Marchianò, Ugo Pastorino

Article2021

A modeling analysis to compare eligibility strategies for lung cancer screening in Brazil

Adalberto Miranda‐Filho, Hadrien Charvat, Freddie Ian Bray, Arn Migowski, Li C. Cheung, Salvatore Vaccarella, Mattias Johansson, André Lopes Carvalho, Hilary A. Robbins

Article2014

Circulating microRNA signature and lung cancer outcome in low-dose computed tomography (LDCT) screening.

Stefano Sestini, Mattia Boeri, Alfonso Marchianò, Giuseppe Pelosi, Carlotta Galeone, Nicola Sverzellati, Carlo La Vecchia, Gabriella Sozzi, Ugo Pastorino